Septerna eyes 2026 trial for new hypoparathyroidism treatment
Biotech company Septerna is currently conducting preclinical tests to identify a lead experimental therapy for hypoparathyroidism, with the hope of starting clinical trials in 2026. “We are executing effectively across our portfolio, with each program nearing important milestones,” Jeffrey Finer, MD, PhD, CEO and co-founder of Septerna, said…